Key Points
- Director Eric Sachetta bought 7,000 shares of Sensus Healthcare on Nov. 21 at $3.93 each (a $27,510 purchase), increasing his stake to 140,113 shares (a 5.26% rise); he also bought 2,500 shares on Nov. 13 at $4.50.
- Sensus shares traded around $4.02 with a 12‑month range of $3.03–$9.33 and a market cap of about $66.0 million, while analysts show mixed views (consensus rating: Hold, average target $8.00).
- In its most recent quarter Sensus reported ($0.06) EPS, beating the ($0.12) estimate, and revenue of $6.88 million versus an expected $6.31 million.
Sensus Healthcare, Inc. (NASDAQ:SRTS - Get Free Report) Director Eric Sachetta purchased 7,000 shares of the business's stock in a transaction that occurred on Friday, November 21st. The shares were purchased at an average price of $3.93 per share, for a total transaction of $27,510.00. Following the completion of the acquisition, the director owned 140,113 shares of the company's stock, valued at $550,644.09. The trade was a 5.26% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Eric Sachetta also recently made the following trade(s):
- On Thursday, November 13th, Eric Sachetta acquired 2,500 shares of Sensus Healthcare stock. The stock was purchased at an average price of $4.50 per share, with a total value of $11,250.00.
Sensus Healthcare Stock Performance
Shares of Sensus Healthcare stock traded up $0.09 during mid-day trading on Friday, hitting $4.02. 57,330 shares of the stock were exchanged, compared to its average volume of 167,282. Sensus Healthcare, Inc. has a 12 month low of $3.03 and a 12 month high of $9.33. The company has a 50-day simple moving average of $3.47 and a 200 day simple moving average of $4.06. The company has a market capitalization of $66.03 million, a P/E ratio of -67.00 and a beta of 1.38.
Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.12) by $0.06. The company had revenue of $6.88 million during the quarter, compared to the consensus estimate of $6.31 million. Sensus Healthcare had a negative return on equity of 1.58% and a negative net margin of 2.26%. Analysts predict that Sensus Healthcare, Inc. will post 0.32 EPS for the current year.
Institutional Investors Weigh In On Sensus Healthcare
Institutional investors have recently made changes to their positions in the stock. American Century Companies Inc. boosted its holdings in shares of Sensus Healthcare by 12.7% in the first quarter. American Century Companies Inc. now owns 22,440 shares of the company's stock worth $106,000 after acquiring an additional 2,520 shares during the period. Geode Capital Management LLC lifted its holdings in Sensus Healthcare by 2.5% during the 2nd quarter. Geode Capital Management LLC now owns 153,917 shares of the company's stock worth $730,000 after purchasing an additional 3,766 shares in the last quarter. Sachetta LLC boosted its stake in Sensus Healthcare by 3.0% in the 2nd quarter. Sachetta LLC now owns 128,675 shares of the company's stock worth $610,000 after purchasing an additional 3,788 shares during the period. IFP Advisors Inc grew its holdings in Sensus Healthcare by 37.2% during the 1st quarter. IFP Advisors Inc now owns 18,800 shares of the company's stock valued at $89,000 after buying an additional 5,100 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in Sensus Healthcare by 3.9% during the 1st quarter. Bank of New York Mellon Corp now owns 141,971 shares of the company's stock valued at $672,000 after buying an additional 5,289 shares in the last quarter. Hedge funds and other institutional investors own 25.30% of the company's stock.
Analysts Set New Price Targets
Several equities analysts recently weighed in on SRTS shares. Zacks Research upgraded shares of Sensus Healthcare from a "strong sell" rating to a "hold" rating in a research report on Wednesday, October 22nd. Lake Street Capital lowered their price target on shares of Sensus Healthcare from $13.00 to $6.00 and set a "buy" rating on the stock in a report on Friday, August 8th. HC Wainwright dropped their price objective on Sensus Healthcare from $12.00 to $8.00 and set a "buy" rating on the stock in a research note on Tuesday, August 12th. Wall Street Zen downgraded Sensus Healthcare from a "hold" rating to a "sell" rating in a research report on Saturday. Finally, Weiss Ratings restated a "sell (d)" rating on shares of Sensus Healthcare in a research note on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $8.00.
View Our Latest Research Report on Sensus Healthcare
About Sensus Healthcare
(
Get Free Report)
Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
